Table 4 Cox proportional hazards analysis of the impact of SATB1 protein expression on overall survival and recurrence free survival in resected pancreatobiliary type and intestinal type periampullary adenocarcinomas
OS | RFS | |||||
|---|---|---|---|---|---|---|
Pancreatobiliary type | HR (95% CI) | n (events) | p† | HR (95% CI) | n (events) | p† |
All cases | ||||||
SATB1 neg | 1.00 | 84 (63) | 1.00 | 84 (69) | ||
SATB1 pos | 2.11 (1.25-3.56) | 21 (19) | 1.87 (1.10-3.18) | 21 (18) | ||
No adjuvant treatment | 0.166 | 0.927 | ||||
SATB1 neg | 1.00 | 40 (30) | 1.00 | 40 (33) | ||
SATB1 pos | 2.94 (1.37-6.29) | 9 (9) | 1.63 (0.71-3.74) | 9 (7) | ||
Any adjuvant treatment | ||||||
SATB1 neg | 1.00 | 44 (33) | 1.00 | 44 (36) | ||
SATB1 pos | 1.70 (0.83-3.52) | 12 (10) | 2.05 (1.02-4.11) | 12 (11) | ||
No gemcitabine | 0.066 | 0.384 | ||||
SATB1 neg | 1.00 | 46 (35) | 1.00 | 46 (38) | ||
SATB1 pos | 3.14 (1.60-6.16) | 12 (12) | 2.05 (1.00-4.20) | 12 (10) | ||
Gemcitabine | ||||||
SATB1 neg | 1.00 | 38 (28) | 1.00 | 38 (31) | ||
SATB1 pos | 1.44 (0.62-3.35) | 9 (7) | 1.60 (0.72-3.56) | 9 (8) | ||
Intestinal type | ||||||
All cases | ||||||
SATB1 neg | 1.00 | 45 (22) | 1.00 | 45 (20) | ||
SATB1 pos | 1.06 (0.47-2.38) | 16 (8) | 1.26 (0.57-2.77) | 16 (9) | ||
No adjuvant treatment | 0.165 | 0.021 | ||||
SATB1 neg | 1.00 | 33 (17) | 1.00 | 33 (13) | ||
SATB1 pos | 1.62 (0.67-3.92) | 10 (7) | 2.69 (1.11-6.51) | 10 (8) | ||
Any adjuvant treatment | ||||||
SATB1 neg | 1.00 | 12 (5) | 1.00 | 12 (7) | ||
SATB1 pos | 0.30 (0.03-2.56) | 6 (1) | 0.18 (0.02-1.46) | 6 (1) | ||
No gemcitabine | 0.649 | 0.143 | ||||
SATB1 neg | 1.00 | 40 (20) | 1.00 | 40 (17) | ||
SATB1 pos | 1.20 (0.51-2.83) | 12 (7) | 1.76 (0.76-4.09) | 12 (8) | ||
Gemcitabine | ||||||
SATB1 neg | 1.00 | 5 (2) | 1.00 | 5 (3) | ||
SATB1 pos | 0.67 (0.06-7.53) | 4 (1) | 0.27 (0.03-2.64) | 4 (1) | ||